Biologics Manufacturing Market Report 2026

The biologics manufacturing market size has grown exponentially in recent years. It will grow from $42.04 billion in 2025 to $50.69 billion in 2026 at a compound annual growth rate (CAGR) of 20.6%. The growth in the historic period can be attributed to expansion of recombinant protein therapeutics, early adoption of mammalian cell culture systems, growth in vaccine manufacturing capacity, increasing outsourcing of biologics production, advancements in purification technologies.

The biologics manufacturing market size is expected to see exponential growth in the next few years. It will grow to $106.08 billion in 2030 at a compound annual growth rate (CAGR) of 20.3%. The growth in the forecast period can be attributed to increasing demand for personalized biologics, rising investments in flexible manufacturing platforms, expansion of biosimilar development, growing adoption of digital bioprocessing tools, focus on cost-efficient large-scale production. Major trends in the forecast period include increasing adoption of single-use bioprocessing systems, rising deployment of continuous biomanufacturing, growing demand for high-volume monoclonal antibody production, expansion of modular biologics facilities, enhanced integration of advanced process control.

The increasing incidence of chronic diseases is anticipated to fuel expansion in the biologics manufacturing market. Chronic diseases represent long-term health issues that progress gradually and persist over time, frequently demanding ongoing medical attention. This surge stems in part from sedentary lifestyles, where extended periods of sitting and limited exercise heighten the chances of ailments like cardiovascular disease and diabetes. Biologics manufacturing supports chronic disease treatment through the creation of precise therapies, proving highly effective for managing diabetes, cancer, and autoimmune conditions. It alleviates the overall disease load by delivering reliable, top-quality biologic drugs, which enhance patient results and optimize therapeutic processes. For instance, in June 2024, the National Health Service - a UK government agency - reported that 3,615,330 patients registered with general practitioners (GPs) had been diagnosed with non-diabetic hyperglycemia or pre-diabetes (elevated blood sugar not severe enough for a diabetes diagnosis) in 2023, reflecting an 18% rise from 3,065,825 cases the previous year. Thus, the escalating prevalence of chronic diseases is propelling the biologics manufacturing market forward.

Major companies in the biologics manufacturing sector are prioritizing the creation of cutting-edge solutions, including unified biologics contract development and manufacturing organization (CDMO) platforms, to streamline comprehensive biologics development, boost production efficiency, and improve supply chain coordination across diverse therapeutic areas. An integrated biologics CDMO platform represents a holistic system that merges biologics development, manufacturing, and supply services into one cohesive framework. For example, in June 2023, Catalent Inc., a US-based contract development and manufacturing firm, broadened its OneBio Suite to deliver integrated development, manufacturing, and supply capabilities for various biologic modalities. The upgraded OneBio Suite introduces a complete biologics CDMO platform supporting antibodies, cell and gene therapies, and mRNA products. It delivers full-spectrum services from development through fill-finish and packaging under a single contract with consistent project management, facilitating quicker timelines, greater scalability, and smooth global supply chain connectivity.

In September 2025, Terumo Corporation, a Japan-based medical technology firm, purchased WuXi Biologics (Cayman) Inc. for an undisclosed sum. This acquisition allows Terumo to boost its CDMO production capabilities and worldwide footprint, strengthening its capacity to deliver comprehensive biologics manufacturing and fill-finish services for injectable treatments. WuXi Biologics (Cayman) Inc., headquartered in China, provides full-spectrum solutions for biologics discovery, development, and production.

Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE.

North America was the largest region in the biologics manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the biologics manufacturing market by increasing costs of imported bioreactors, chromatography resins, filtration membranes, sensors, and automation systems essential for upstream and downstream processing. Manufacturing facilities in North America and Europe are most impacted due to reliance on imported high-end bioprocess equipment, while Asia-Pacific faces higher costs for export-focused production expansion. These tariffs are elevating capital investment requirements and extending facility commissioning timelines. However, they are also promoting domestic equipment manufacturing, regional supply chain strengthening, and increased adoption of locally sourced bioprocess technologies.

The biologics manufacturing market research report is one of a series of new reports that provides biologics manufacturing market statistics, including biologics manufacturing industry global market size, regional shares, competitors with a biologics manufacturing market share, detailed biologics manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the biologics manufacturing industry. This biologics manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics manufacturing involves the intricate production of medications sourced from living organisms or their parts. It entails growing genetically modified cells or microbes in bioreactors to produce therapeutic proteins or other biologic substances, then applying purification methods such as filtration and chromatography to guarantee safety and purity. This approach facilitates the creation of secure, potent, and superior biologic therapies, advancing personalized treatments and enhancing patient results.

The primary approaches to biologics production are contract manufacturing and in-house manufacturing. Contract manufacturing involves a company outsourcing the production of its biologic products to a specialized third-party provider. Key modalities encompass monoclonal antibodies (mAbs), biosimilars and recombinant proteins, vaccines, cell and gene therapies, and RNA-based therapeutics, targeting oncology, autoimmune conditions, infectious diseases, neurological disorders, and various other indications.

The biologics manufacturing market consists of sales of therapeutic proteins, enzymes, recombinant DNA products, blood factors, and other biologic-based therapeutics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.